TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Dr. Mikhak will be responsible for the clinical development of the Company’s pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder clinical programs.
Related news for (TFFP)
- TFF Pharmaceuticals Announces It Will Wind Down Operations
- tff pharmaceuticals’ technology generates superior inhalational dry powder formulations for pulmonary drug delivery
- tff pharmaceuticals announces positive preclinical data from bivalent universal influenza vaccine candidates manufactured by tff following intranasal immunization
- tff pharmaceuticals to present at the h.c. wainwright 26th annual global investment conference
- TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference